InflaRx NV has announced a strategic focus on capital-efficient execution centered around the development of izicopan, its lead pipeline asset. The company plans to advance izicopan toward Phase 2b readiness in hidradenitis suppurativa (HS) and broaden its evaluation in additional inflammation and immunology (I&I) indications. InflaRx intends to conduct a pharmacokinetic $(PK)$ bridging study in China in 2026 to facilitate expedited proof-of-concept studies in China and other regions. The company is also pursuing collaborations to accelerate izicopan’s development across I&I indications. As part of this strategy, InflaRx is implementing a workforce reduction of approximately 30% and reducing expenditures on non-essential activities, including Gohibic (vilobelimab), to extend its cash runway to mid-2027. A virtual Capital Markets Day is planned for spring 2026 to present the clinical utility and commercial potential of izicopan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622250-en) on January 08, 2026, and is solely responsible for the information contained therein.